Biogen Loses Four Years Of EU Tecfidera Exclusivity
This article was originally published in Scrip
The European Patent Office has revoked one of the few remaining patents covering Tecfidera (dimethyl fumarate) in Europe. The method of use patent (EP2137537) covers the use of 480mg of Tecfidera for the treatment of multiple sclerosis, which is the labeled dose of Tecfidera.
Register for our free email digests: